Volume 13 | November 2020

Visit our Website

Kidney Cancer News

#KCRS20 KidneyCAN is proud to announce the 2nd annual Kidney Cancer Research Summit, a meeting focused on basic and translational science, as well as cutting edge translational research. This work is fueled by the funding from the Department of Defense CDMRP – KCRP. We were lucky enough to have Dr. William G. Kaelin, Jr. as our keynote speaker, where he even showed us his Nobel Prize! We hope you will visit our website even if you missed the event to see the recorded presentation videos.

IKCC Global Patient Survey We are pleased to announce we are participating in IKCC Global Patient Survey about kidney cancer. We invite all patients, caregivers and survivors to share their experience and improve the global and local understanding of kidney cancer.

Click HERE to take Patient Survey

Check out KidneyCAN  District Days! On August 12-13, 2020, KidneyCAN organized our first District Days. 122 advocates from 29 states participated in 115 conference call meetings during this remote Hill Day.

ESMO Virtual Congress 2020: Kidney ccRCC Immune Classification Enhances the Predictive Value of T Effector and Angiogenesis Signatures in Response to Nivolumab The NIVOREN GETUG-AFU 26 is a phase II multicenter prospective cohort study aimed at assessing the safety and efficacy of nivolumab among patients with metastatic renal cell carcinoma (mRCC) following the progression of one or two tyrosine kinase inhibitors in a “real world” setting. The results of this trial were reported at the 2019 ASCO Genitourinary Cancers Symposium. The results of this study demonstrated that “real world” use of nivolumab had similar safety and efficacy as reported in the pivotal CheckMate 025 trial.

Exelixis Announces Results From Two Renal Cell Carcinoma Cohorts of the COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab

Exelixis announced positive phase 1b clinical trial results for the combination of cabozantinib (CABOMETYX®) and atezolizumab (TECENTRIQ®) in patients with locally advanced or metastatic solid tumors.

Study Demonstrates Improved Responses With Molecularly-Guided Therapy in mRCC  Findings from the noncomparative, phase 2, biomarker-driven BIONIKK trial demonstrated clinical evidence to support the use of molecularly-directed frontline therapy as means to enrich responses in patients with metastatic clear cell renal cell carcinoma (ccRCC).

Subscribe to the newsletter

KIdneyCAN is the voice of kidney cancer advocacy. We have been instrumental in obtaining $40 million for FY'20 research funding for Kidney Cancer through the DoD CDMRP Program. Our goal is $50 million for kidney cancer research in FY'21. Please consider supporting KidneyCAN's Advocacy for research and direct research funding.

Donate Now

About The KidneyCAN Newsletter: We scan the web for the latest relevant research and share the best here. If we missed a great one, please contact us and share it with us. We need your help to get the word out. Please sign up your friends for the newsletter, both patients and caregivers. Share this newsletter on Facebook, Twitter or Instagram. And come talk with kidney cancer patients (including us) on SmartPatients.com

Subscribe to the newsletter

E-mail us

Disclaimer:The material in this newsletter is for informational purposes only and is not a substitute for professional medical advice. Consult with a qualified healthcare provider with any questions or concerns you may have.

KidneyCAN/ Kidney Cancer Coalition | Tel: 202-431-2727 | [email protected]

STAY CONNECTED ‌ ‌ ‌